NCT04110964View on ClinicalTrials.gov

Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT

PHASE1UnknownINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Critical Limb Ischemia
Interventions
DRUG

AAV-hTERT

subjects will receive a single LGT (AAV-hTERT) treatment via IV administration

Trial Locations (1)

250251

RECRUITING

IPS Arcasalud SAS, Zipaquirá

Sponsors
All Listed Sponsors
lead

Libella Gene Therapeutics

INDUSTRY